Testosterone and Pain Sensitivity
WithdrawnPhase 4NCT01689896
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This research is being done to see whether testosterone replacement in men who take opioid-based pain medications and have low testosterone levels will show improvement in pain tolerance, pain perception and quality of life. Some men who take opioid-based medications (narcotics) for pain develop low testosterone levels. Research has shown that low testosterone levels may make a person more sensitive to pain. This means that if a person with a painful condition develops low testosterone level as a result of his pain medications, he might become more sensitive to pain and so may need higher doses of pain medications for pain control. Testosterone is a male hormone that is important for sperm production and the development of male characteristics such as muscle mass and strength, fat distribution, bone mass and sex drive. Testosterone hormone replacement therapy has been used for decades to treat men with low testosterone levels (male hypogonadism). Testosterone replacement therapies are available in the form of an injection into the muscle, implants under the skin, oral capsules taken by mouth, topical gels applied to the skin, and skin patches. This study will use Fortesta®, a topical testosterone gel (T-gel) absorbed into the skin. Fortesta® is currently on the market as an FDA-approved treatment of male hypogonadism (low testosterone levels). Men with non-cancer related pain who take opioid-based medications for pain and have low testosterone levels may join this study. (A low testosterone level is defined as early morning (before noon) blood testosterone level of 300 ng/dl or less, or a free testosterone of 50 ng/dl or less)).
Study details
- Official title
- Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception in Men With Chronic Pain Syndrome
- Conditions
- Low Testosterone
- Hypogonadism
- Pain
- Interventions
- Drug: Testosterone Gel
- Drug: Placebo Gel
- Sponsor
- Johns Hopkins University
- Collaborators
- Endo USA Inc., a Keenova Therapeutics Company
- Start date
- 2012-08
- Primary completion
- 2015-03
- Sex
- Male
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Men * 18 Years of Age and Older * Serum total testosterone level \<300 ng/dl or free testosterone \< 50 pg/ml * Consumption of at least 10 mg of hydrocodone (or analgesic equivalent of another opioid) for at least 4 weeks * Absence of hospitalization in past 2 months * No acute illness in past 2 months * No prior history of any form of hypogonadism * No current anabolic therapy (growth hormone, DHEA, etc) * No current use or consumption in past 2 months of glucocorticoids and melatonin * Normal digital rectal examination * Normal PSA level Exclusion Criteria: * Liver enzymes \>3 times upper limit of normal * Serum creatinine \> 2 times upper limit of normal * Neurological disease * Active psychiatric illness * Any addictive and/or illicit drug use * Alcoholism (\>10 drinks/week) * Patients currently receiving glucocorticoids, melatonin or anabolic agents * Hospitalization in past 2 months * Acute illness in past 2 months * Consumption of \< 20 mg of hydrocodone (or analgesic equivalent of another opioid) * Severe BPH * PSA \>4.0 ng/ml * Prostate cancer * Breast cancer * Any cancer or cancer related pain * History of alcohol abuse * Known peripheral neuropathy (any etiology) or peripheral vascular disease (including Raynaud's disease), which may interfere with pain testing * Concurrent warfarin treatment
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01689896